Target, across the briefings
MS4A1 across 4 cancers
MS4A1 is on the target list of 4 of the briefings. A drug aimed at it carries an FDA label naming the disease in 3, and is approved for some indication in 4.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Follicular lymphoma | approved here Epcoritamab, Glofitamab, Mosunetuzumab, Obinutuzumab, Rituximab | approved | 18 | 22 via CD20 |
| Diffuse large B-cell lymphoma | approved here Epcoritamab, Glofitamab, Rituximab | approved | 18 | 32 via CD20 |
| Chronic lymphocytic leukemia | approved here Obinutuzumab, Rituximab | approved | 18 | 35 via CD20 |
| Hodgkin lymphoma | approved elsewhere | approved | 18 | 32 via CD20 |
"Approved here" means a drug Open Targets records as aimed at MS4A1 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.